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ABSTRACT
RNA interference (RNAi) mediates gene silencing in
many eukaryotes and has been widely used to invest-
igate gene functions. A common method to induce
sustained RNAi is introducing plasmids that syn-
thesize short hairpin RNAs (shRNAs) using Pol III pro-
moters. While these promoters synthesize shRNAs
and elicit RNAi efficiently, they lack cell specificity.
Monitoring shRNA expression levels in individual
cells by Pol III promoters is also difficult. An alternat-
ive way to deliver RNAi is to use Pol II-directed syn-
thesis ofshRNA.Previous efforts in developinga Pol II
system have been sparse and the results were con-
flicting, and the usefulness of those Pol II vectors has
been limited due to low efficacy. Here we demon-
strate a new Pol II system that directs efficient
shRNA synthesis and mediates strong RNAi at levels
that are comparable with the commonly used Pol III
systems. In addition, this system synthesizes a mar-
ker protein under control of the same promoter as the
shRNA, thus providing an unequivocal indicator, not
only to the cells that express the shRNA, but also to
the levels of the shRNA expression. This system may
be adapted for in vivo shRNA expression and gene
silencing.
INTRODUCTION
RNA interference (RNAi) can mediate sequence-specific post-
transcriptional gene silencing in many eukaryotes. In RNAi,
long double-stranded RNA or short hairpin RNA (shRNA) is
cleaved to produce short RNA duplexes 21–23 nt in length
with 2 nt overhangs at the 30 end (1,2). Dicer, an RNase III
enzyme, catalyzes this cleavage (3). Together with R2D2
(a small RNA binding protein), dicer also facilitates the
formation of RISC (RNA-induced silencing complex),
which in mammalian cells minimally contains a short,
single-stranded RNA and a protein Argonaute2 (4–6). RISC
identifies, binds and cleaves the complementary RNA (7).
Because of its sequence specificity, RNAi has been widely
used to silence specific genes for investigation of the gene
functions. In mammalian cells, this is accomplished by intro-
ducing small interfering RNAs (siRNAs) (8) or short hairpin
RNAs (shRNAs) into cells (9). The siRNAs are composed of
two RNA strands with 19 nt duplexes and 2 nt overhangs at the
30 ends. The shRNAs are usually delivered as gene constructs
that are composed of a promoter, a short DNA sequence
encoding an shRNA and a transcription termination sequence.
The structure of shRNA mimics pre-micro RNAs (pre-
miRNAs), which are endogenously encoded natural shRNAs
that are synthesized and processed into miRNAs, which are
single stranded. miRNAs also complex with Argonaute pro-
teins to form RISC, which is capable of mediating both
RNAi and translational repression (10).
Due to their potential for sustained RNAi, shRNAs
have been often applied for in vivo gene silencing. They
have been delivered using viral vectors or being directly
injected into fertilized oocytes for making transgenic mice
(11–13). Most constructs have used Pol III promoters, includ-
ing U6, H1 and tRNA promoters (12,14,15). The advantages of
these promoters are that they direct high levels of shRNA
expression, which in turn mediates highly efficacious silen-
cing. In addition, the gene construct is small and simple, and
easily inserted into viral vectors. The limitation of these
constructs is that these promoters have no cell specificity,
and exceedingly high levels of shRNA expression increases
the probability of off-target silencing and elicit non-specific
effects such as interferon response and cellular toxicity
(16,17).
*To whom correspondence should be addressed. Tel: +1 508 856 3309; Fax: +1 508 856 8390; Email: zuoshang.xu@umassmed.edu
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
ª The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.org
Nucleic Acids Research, 2005, Vol. 33, No. 6 e62
doi:10.1093/nar/gni061
 Published online April 1, 2005
Compared with Pol III promoters, Pol II promoter-directed
synthesis of shRNAs may be advantageous in some circum-
stances. For example, many cell- or tissue-specific Pol II
promoters are known and have been successfully used in
transgenic mice. These promoters may be used to direct
cell- or tissue-specific gene silencing. Furthermore, while
no evidence indicates that Pol III synthesizes miRNAs,
some miRNAs are known to be downstream of Pol II pro-
moters, are within known protein coding genes and are ex-
pressed by Pol II activity (18,19). Therefore, strategies using
Pol II-directed synthesis of shRNA mimic the natural miRNA
synthesis and could be an efficient RNAi strategy in vivo.
Limited attempts have been made to test the potential of
shRNA-mediated silencing using Pol II promoters. Four
groups have used the cytomegalovirus (CMV) promoter
to synthesize shRNAs. Three used the CMV promoters to
synthesize miRNAs that contained the shRNA but no
protein-coding sequences (11,20,21). Among these two repor-
ted successful silencing (11,20), while one reported low
efficacy (21). The fourth group placed the hairpin in the
30-untranslated region (30-UTR) of a GFP coding sequence
and observed silencing (22). In a new study, a cell-specific
promoter was used to synthesize shRNA and silencing was
observed in a specific cell group (23).
Although these studies showed that pol II-directed synthesis
of shRNA was useful for gene silencing, the efficacy of dif-
ferent constructs was not quantitatively compared, and there-
fore, the optimal construct design was not clear. Furthermore,
the relative RNAi efficacy of these constructs in comparison
with the pol III constructs was not known. In the experiments
where the plasmid concentrations were reported, high ratios
of the shRNA-synthesizing plasmid to the target plasmid,
ranging from 8 to 1 to 80 to 1, had to be used to observe
silencing (20,22), suggesting that those constructs were relat-
ively inefficient compared with the Pol III-hairpin constructs.
In the present work, we tested several new strategies for
Pol II-directed synthesis of shRNA and their silencing effici-
ency. Using the CMV promoter, we tested a series of vari-
ations of hairpins that mimic a human miRNA miR-30
structure (24). We found that the hairpins that adopted the
authentic miR-30 structure mediated the most effective silen-
cing. Furthermore, we placed this hairpin in an intron down-
stream of another Pol II promoter, the human ubiquitin C
(UbC) promoter. This construct mediated silencing with the
efficiency that was comparable with the widely used Pol III-
hairpin constructs. Finally, we tested silencing using the same
strategy against a different gene and demonstrated that this
strategy can silence endogenous gene expression and function.
MATERIALS AND METHODS
Plasmid construction
The shRNA sequences are shown in the figures. To construct
CMV promoter-driven shRNA vectors, DNA oligonucleotides
were chemically synthesized and annealed to form double-
stranded DNA fragments that were inserted between the re-
striction sites KpnI and EcoRI in the polylinker of the carrier
vector pcDNA3 (Invitrogen). To construct the tandem shRNA
vector, the first DNA oligonucleotide was inserted between
KpnI and EcoRI, and the second between XbaI and NotI of
pcDNA3 plasmid. The two shRNA stem–loop structures were
separated by 100 nt sequence from the neomycin gene
(Figure 1).
To construct human ubiquitin C (UbC) driven shRNA
vector, the human ubiquitin C (UbC) promoter, including
350 bp upstream from transcription initiation site, first
exon and the first intron (25), were cloned from the genomic
DNA of human embryonic kidney 293 cells (HEK293) by
PCR and inserted into pEGFP-N1 (Clonetech) to replace
the CMV promoter. Two restriction sites KpnI (+530 bp)
and EcoRI (+535 bp) were then introduced inside the first
intron of the UbC sequence. The DNA oligonucleotides cod-
ing for the shRNAs were inserted between KpnI and EcoRI.
The U6-shRNA vector was constructed as described
previously (26). To construct the H1-shRNA vector, human
H1 promoter was cloned from the genomic DNA of HEK293
cells by PCR and placed into pUC19 vector.
To facilitate the analysis of shRNA efficacy, human SOD1
opening reading frame was inserted into the 30 untranslated
region 100 bp downstream from firefly luciferase opening
reading frame in the pGL2 vector (Promega). All constructs
were sequence-verified.
Cell culture and transfection
HEK293 cells were grown in DMEM medium supplemented
with 10% fetal bovine serum (FBS), 100 U/ml penicillin and
100 mg/ml streptomycin. Twenty-four hours before transfec-
tion, cells (70–90% confluence) were detached by trituration,
transferred to 6-well or 24-well plates and cultured in 10%
FBS-containing medium without antibiotics. The cells were
transfected in the absence of serum with the transfection
reagent lipofectamine-2000 (Invitrogen) according to manu-
facturer’s instructions. Four hours later, the FBS was added
back. The growth medium was changed every 24 h.
Neuroblastoma-spinal cord 34 (NSC-34) cells (27) were
cultured and transfected similarly as the HEK293 cells. Twenty
four hours after transfection of the Pol II-shRNA-EGFP vector,
the cells were selected with 100 mg/ml zeocin (the zeocin-
resistant gene was inserted into the shRNA-expressing vector).
Individual colonies were picked and expanded. The expression
levels of the transgene were evaluated by monitoring
EGFP fluorescence. Cell lines with desired expression levels
were maintained in DMEM containing 10% FBS, 100 U/ml
penicillin, 100 mg/ml streptomycin and 50 mg/ml zeocin.
Northern blotting analysis
HEK 293 cells were grown in 6-well plates and transfected
with 2 mg of each plasmid per well. After 30 h of transfection,
the cells were harvested and used for total RNA extraction
with Trizol reagent (Sigma). Twenty micrograms of total RNA
was fractionated on a 15% polyacrylamide gel and transferred
onto HybondTM-N+ membrane (Amersham). After UV cross-
linking, the membrane was probed with 32P-labeled synthetic
RNA oligonucleotide complementary to the antisense strand
of the human SOD1 shRNA.
Luciferase assay
HEK293 cells were transfected in 24-well culture plates
using 0.25 mg of either shRNA-expressing vector or empty
pcDNA3 plasmid, 0.25 mg of firefly luciferase (Pp-luc) vector
e62 Nucleic Acids Research, 2005, Vol. 33, No. 6 PAGE 2 OF 8
with human SOD1 cDNA sequence at 30-UTR (pGL2-luc-
sod1), and 0.15 mg of renilla luciferase (Rr-luc) expressing
vector pRL-TK as transfection control. The cells were
harvested at 28 h after the transfection. The luciferase activity
in the cleared cell lysate was measured with the Dual
Luciferase assay kit (Promega, Madison, WI) using a
Mediators Diagnostika (Vienna, Austria) PhL luminometer.
The luciferase activity was defined as the ratio of Pp-luc
activity from pGL2-control derivative to Rr-luc activity
from pRL-TK. Thereafter, the relative luciferase activity
was normalized to the control transfected with the empty
vector pcDNA3 plus two luciferase-expressing vectors.
Immunoblots
HEK 293 cells were transfected twice in 6-well plates at 0 and
24 h, and split and plated onto 24-well plates at 48 h after
the initial transfection. At 72 h, the cells were harvested
for protein extraction. NSC-34 cell lines stably expressing
the shRNA transgenes were collected from 6-well plates and
pelleted. The cell pellets were lysed in ice-cold lysis buffer
containing 0.4% NP-40, 0.2 mM Na3VO4, 20 mM HEPES
(pH 7.9) and a cocktail of protease inhibitors (Complete-
Mini, Sigma). Cell pellets were homogenized by short
sonication and protein content in the cleared lysate was
determined using the BCA assay (28). Fifty micrograms of
Figure 1. Design of the Pol II-driven hairpin vectors. In the first group of constructs, hairpins 1–9 were placed behind the CMV promoter. The hairpin structures
were variations of human miR-30, which was represented by hairpin 8. The antisense strand of the miR-30 hairpin stem was replaced with the sequence that
was complementary with the coding region of human SOD1 mRNA (light letters). The loop sequence of miR-30 was preserved since its variations have been
investigated previously (20). Eight variations at the base of the hairpin stem were created (hp 1–7, 9). The sequences flanking either side of the hairpins shown here
were derived from the neomycin-resistant gene (neo). Transcription was terminated using bovine growth hormone poly(A) sites. Construct 10 contained two tandem
hairpins, both of which were hp 8. In construct 11, the CMV promoter was replaced with the ubiquitin C (UbC) promoter, which included the first intron. Hairpin 8 was
inserted in the intron. For comparison, constructs 12 and 13 used U6 and H1 promoters, respectively, for the synthesis of the shRNA against SOD1.
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total proteins were resolved on 15% SDS–PAGE gel and
blotted onto GeneScreen Plus membrane (Perkin Elmer).
Proteins were detected using specific primary antibodies and
SuperSignal kit, and photographed using the Kodak Digital
Image Station 440CF. The primary antibodies were sheep
anti-superoxide dismutase-1 (SOD1; 1:1000; BioDesign), rab-
bit anti-Mn superoxide dismutase (SOD2; 1:1000, Stressgen)
and mouse anti-glyceraldehye-3-phosphate dehydrogenase
(GAPDH; 1:10000; Abcam). After detection of either SOD1
or SOD2, the membrane was stripped for 30 min at 55C in
100 mM b-mercaptoethanol, 2% SDS (w/v) in 62.5 mM Tris–
HCl (pH 6.7) and used again for detecting immuno-reactivity
of GAPDH, which served as loading control.
Cell viability assay
After two transfections and splitting as described above (see
‘Immunoblot Analysis’), HEK 293 cells were grown in 24-
well plates for another 24 h. After exposure to 300 mM H2O2
for 4 h, the cells were rinsed twice with PBS and cultured in
normal medium containing 10% FBS for another 20 h (this
minimized overestimation of cell death resulting from direct
inhibition of mitochondria dehydrogenase by H2O2). Cell
viability was determined using an MTS assay kit according
to manufacturer’s instructions (Promega). The CellTiter 961
AQueous One Solution Reagent was directly added to growth
medium and incubated for 4 h before measuring absorbance at
495 nm with a 96-well plate reader. The absorbance of lysates
was normalized to the average absorbance of the untreated
cells. Statistical analysis was performed using ANOVA
followed by Tukey post hoc test to compare group means.
Fluorescence activated cell sorting (FACS)
Mouse embryonic cell line NF-1 (ATCC) was maintained in
DMEM medium containing 10% FBS, 100 U/ml penicillin
and 100 mg/ml streptomycin. The cells were transfected
with construct 11 (UbC-SOD2hp-EGFP) in the presence
of 5% FBS. Forty-eight hours after transfection, the cells
were separated into four groups using FACS based on their
levels of eGFP fluorescence: group 1, 5.5–25 · 104 (arbitrary
units); group 2, 2–7 · 103; group 3, 2–10 · 102; and group 4,
0–50. Approximately 1.5–2 million cells were collected
for each group. The cells were lysed and immunoblotted
for eGFP, SOD2 and GAPDH as described above.
RESULTS AND DISCUSSION
To find the optimal construct for Pol II-directed synthesis of
shRNA, we made a series of variants of human miR-30 hairpin
structure (Figure 1). We chose miR-30 as a model hairpin
structure because its stem sequence could be substituted
with other sequences that match different targets (20,29).
Because the previous studies suggested that simplifying
miR-30 structure by eliminating the mismatch, the bulge
and most of the base sequence does not significantly alter
the RNAi efficiency (20,29), we first constructed a similar
hairpin and a series of its variations (Figure 1, constructs 1–
7). These hairpins targeted the human SOD1 mRNA and were
placed downstream from the CMV promoter in an mRNA
transcript. This construct design was similar to several
previously published Pol II-shRNA synthesizing constructs
(20,29). In cotransfections with a report luciferase construct
that contains the target sequence in its 30-UTR, most of these
hairpins (1–6 and 9) were expressed (Figure 2A) and mediated
RNAi against the target (Figure 2B), albeit all at lowered
efficiency compared with the construct that carried the un-
modified miR-30 hairpin structure (Figure 1, construct 8;
and Figure 2). The expression of construct 7 was not detected,
nor was its RNAi efficacy (Figures 1 and 2). This lack of
expression of shRNA in construct 7 is unlikely to be caused
by RNA degradation as shown by ethidium bromide staining
of this gel before transferring (data not shown). Rather, it
might be caused by a lack of processing due to the relatively
drastic change from the authentic miR-30 structure in this
construct.
To determine whether RNAi efficiency might be further
increased by including more sequences from the pri-miR-30
RNA that flank the hairpin, we tested a construct that con-
tained 100 bp on either side of the miR-30 hairpin sequence
A
B
Figure 2. Comparisons in the levels of shRNA expression and in silencing
efficacy. (A) Northern analysis of SOD1-shRNA expression under control of
either Pol-II or Pol-III promoters. Each lane was loaded with equal amount of
total RNA (20 mg/lane) extracted from HEK 293 cells transfected with indi-
cated shRNA constructs. The equal loading was verified by staining the gel
with ethidium bromide before transferring the RNA to the membrane (data
not shown). Lane numbers correspond to the construct numbers shown in
Figure 1. (B) Silencing activity of each construct. HEK 293 cells were trans-
fected with Rr-luc-sod1 and Pp-luc plasmids together with various shRNA
constructs against human SOD1 mRNA, located at 30-UTR of firefly luciferase
(Pp-luc)gene.Renilla luciferase (Rr-luc)plasmidserved as transfection control.
All luciferase activities were normalized to the value measured in the lysate
from cells transfected with the empty vector pcDNA3 (carrier). The values are
means with SD (n = 6). The construct numbers match with those in Figure 1.
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from the pri-miR-30. In agreement with a previous report (30),
the RNAi efficiency was not further enhanced from hairpin
8 (data not shown), suggesting that the authentic miR-30 hair-
pin 8 contains the essential elements for RNAi mediated by
Pol II-synthesized shRNA.
Thus, it is noticeable from the above results that those
hairpins with fewer structural alterations from miR-30 have
RNAi efficiency closer to the hairpin with the authentic miR-
30 structure (Figure 1, construct 8). For example, Hairpin 1
and 9, which had fewest structural alterations (Figure 1),
mediated RNAi slightly less efficiently than hairpin 8
(Figure 2). In contrast, those with large structural alterations
from miR-30 were far less effective or completely ineffective
in RNAi (e.g. hairpins 6 and 7, see Figures 1 and 2). Inter-
estingly, the least effective shRNAs share the lacking of the
distal A/C bulge from the stem (Figures 1 and 2, hairpins 5–7),
suggesting that this distal bulge is an important structural
element of miR-30. Taken together, these results suggest that
the authentic miR-30 structure is the most efficient in RNAi
mediated by Pol II-synthesized shRNA in mammalian cells.
Our results differ from a previous study, in which a Pol II
synthesized hairpin similar to hairpin 7 was shown to be pro-
cessed correctly to form mature miRNA and mediate RNAi
similar to hairpins with the authentic miR-30 structure (20,29).
The reason for this difference is not clear. One possibility is
the difference in the mRNA sequences that harbor the hairpin
between these two studies and these differences could lead to
different processing of the transcripts. In terms of the RNAi
efficiency, we note that in the previous experiments a high
ratio of shRNA-synthesizing plasmid to the target plasmid
(16:1 to 80:1) was used. Consequently, the RNAi effects
might be saturated and the differences between the hairpins
with the authentic miR-30 structure and other variations might
not be revealed. In our experiments, the ratio of shRNA-
synthesizing plasmid to the target plasmid was one to one.
Knowing that the authentic miR-30 hairpin structure was
the best for the Pol II-directed hairpin expression and RNAi,
we tested the efficacy of this hairpin by placing it in two
additional constructs. In the first, we tried to enhance the
RNAi efficacy by placing two hairpins targeting the same
sequence in the human SOD1 gene downstream of the Pol
II promoter (Figure 1, construct 10) in order to produce more
of the shRNA. This reasoning has precedents since some
miRNA genes are located on the same chromosome as clusters
with intervals as short as a few nucleotides and are expressed
with similar profiles (18,24). Such an organization suggests
that these miRNA genes are expressed under control of the
same promoter and their nascent transcripts are processed to
become mature miRNAs. Recent experiments supported this
notion (31). Surprisingly, construct 10 failed to enhance
the expression of shRNA and siRNA (Figure 2A), resulting
instead in a decrease in RNAi efficacy (Figure 2B).
In the second construct, we placed the hairpin downstream
of a different Pol II promoter, the human ubiquitin C promoter.
This promoter has been used for constructing genes that were
placed in transgenic mice and has been shown to efficiently
express transgenes ubiquitously in multiple transgenic lines
(25,32). We placed the hairpin 8 in the first intron, which was
part of the promoter cassette. Downstream of the first intron,
we placed the eGFP open reading frame (Figure 1, construct
11). The rationale for this design was based on recent evidence
that some miRNAs are located in the non-coding regions or
introns of mRNAs for known genes (18). Since synthesis of
both the shRNA and the eGFP depends on the same promoter,
their expression in the same cells is assured. This provides a
convenient way to monitor the cells in which the shRNAs are
expressed, not only qualitatively, but also quantitatively. This
UbC-shRNA-EGFP construct expressed shRNA at a similar
level as the CMV promoter (construct 8) and mediated RNAi
as efficiently (Figure 1, construct 11; and Figure 2). Overall,
the Pol III promoters still expressed at higher levels of shRNA
and mediated stronger target silencing (Figure 1, constructs 12
and 13; and Figure 2). However, the best Pol II constructs,
8 and 11, are approaching the levels of RNAi efficacy of the
Pol III constructs (Figure 2).
Can the Pol II-hairpin construct silence the endogenously
expressed genes? To answer this question, we transfected
the most effective hairpin constructs into the HEK293 cells.
Compared with the controls, the best hairpin constructs 8 and
11 significantly inhibited the endogenous SOD1 expres-
sion (Figure 3A). Construct 11a, which was promoted by
the UbC promoter but without the eGFP open reading
frame, inhibited SOD1 expression similarly as construct 11,
Figure 3. Pol II-directed synthesis of shRNA silenced the endogenous SOD1
expression and SOD1 function. (A) CMV and UbC promoter-directed syn-
thesis of shRNAs knocked down the endogenous SOD1 in HEK 293 cells.
HEK 293 cells were transfected with control and shRNA-expressing constructs
and SOD1 levels were observed using western blot (see Methods). Each lane
was loaded with 50 mg of total protein. After detecting SOD1, the same mem-
brane was stripped and probed again with antibody recognizing glyceral-
dehye-3-phosphate dehydrogenase (GAPDH). Lanes were labeled with the
construct numbers shown in Figure 1. Construct 8-mut had the hairpin sequence
(antisense) 50-GAAUCUUCAAGUCACACAUCGGC-30, which contained
3 bp (underlined) that mismatched with the SOD1 target. Construct 11a
was the same as construct 11 (Figure 1) but without EGFP open reading
frame. (B) CMV and UbC promoter-directed synthesis of shRNAs sensitized
HEK 293 cells to the toxicity of H2O2 (see Methods). Transfected cells were
treated with 300 mM of H2O2 and the cell viability was measured using MTS
assay. Mean values are from six independent experiments and error bars
represent standard error of means. * indicates P < 0.01 when compared with
carrier vector-transfected cells with or without H2O2 stimulation, or compared
with 8-mut transfected cells.
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indicating that eGFP did not interfere with the silencing ac-
tivity of construct 11. To further confirm this silencing, we
tested the function of SOD1 in these cells. Since a lack of
SOD1 is known to enhance cell’s vulnerability to H2O2 tox-
icity (33), we treated the cells with H2O2. Transfection with
construct 8 and 11a significantly reduced the cell viability after
the H2O2 treatment as compared with the control vectors (car-
rier vector and 8-mut) transfection (Figure 3B).
These experiments demonstrated that Pol II-directed syn-
thesis of shRNA against SOD1 can mediate efficient RNAi.
However, it was unclear whether this construct design was
applicable to other target sequences and in different cell
types. Furthermore, it remained unclear whether the eGFP
expression provides a good indicator for the expression of
the shRNA. To resolve these issues, we replaced the human
SOD1 sequence in hairpin 8 with a sequence that target mouse
Mn2+ superoxide dismutase (SOD2) (Figure 4A) and placed
these hairpin in construct 11 (Figure 1). This construct along
with the controls was transfected into NSC-34 cells. Because
the transfection efficiency in these cells were lower
(50%) than in HEK293 cells (>90%), we selected clones
that were transfected with the UbC-SOD2hp-eGFP vector.
After expanding these clones, the SOD2 levels were measured.
Different clones inhibited SOD2 expression differently
(Figure 4B). Clone 3 inhibited SOD2 expression the most,
followed by clones 5 and 4. The different levels of inhibition
were correlated with the eGFP expression (Figure 4C, lower
panels) and cellular toxicity. Clone 3 expressed the highest
level of eGFP, followed by clones 5 and 4. Compared with
the untransfected cells or cells transfected with the mutant
Figure 4. UbC-hp-EGFP provides a convenient indicator for shRNA expression. (A) The shRNA (antisense) sequence against Mn2+ superoxide dismutase (SOD2)
was incorporated into the hairpin 8 structure and inserted into construct 11 (see Figure 1). A mutant hairpin construct that mismatched with SOD2 (SOD2-shRNA-
mut) was also made as a control. (B) UbC-SOD2hp-EGFP expressed EGFP and knocked down endogenous SOD2 in stably transfected NSC34 cells. Western blot
was similarly done as described in Figure 3 excepting using anti-SOD2 as the primary antibody. Lane 1, untransfected NSC 34 cells; lane 2, cells stably transfected
with UbC-SOD2hpMut-EGFP; lane 3, cells transfected with UbC-SOD2hp-EGFP that express EGFP at high level; lanes 4 and 5, cells transfected with UbC-
SOD2hp-EGFP that express EGFP at lower levels. (C) Morphology of NSC34 cells. NSC34 cells were photographed under a microscope using phase contrast (upper
panels) and fluorescence (lower panels). The numbers correspond to those in (B). (D) NF-1 cells transfected with construct 11 were separated into four groups based
on their eGFP fluorescence levels, from the highest in group 1 to the lowest in group 4 (see Methods). Proteins from these cell groups were immunoblotted for eGFP
and SOD2 levels, with GAPDH as the loading control.
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SOD2 hairpin (clone 2), all cell clones that expressed SOD2
shRNA were unhealthy, the degree of which appeared more
severe in clones 3 and 5 than clone 4 (Figure 4C, upper panels).
Clones 3 and 5 expressed more eGFP than clone 4 (Figure 4C,
lower panels). All clones that expressed eGFP and SOD2
shRNA could not be maintained for the long term, probably
due to the cellular toxicity of SOD2 knockdown.
To further confirm the quantitative correlation between the
eGFP expression and the degree of silencing, we sorted cells
that were transfected with construct 11 into four groups based
on their eGFP expression levels. Proteins extracted from
these cell groups were immunoblotted for eGFP and SOD2
(Figure 4D). The levels of eGFP were inversely correlated
with the levels of SOD2, indicating that eGFP was a good
indicator for the levels of shRNA expression and silencing
efficacy.
Taken together, we have demonstrated that, by adopting
the authentic miR-30 hairpin structure, Pol II can direct
shRNA synthesis and mediate gene silencing with high effi-
ciency comparable to Pol III. Therefore, this Pol II-hairpin
design offers an alternative to Pol III constructs. Because the
shRNA expression is under the control by same promoter as
the indicator protein, the indicator protein indicates not only
the cells that express the shRNA, but also the levels of the
shRNA expression. This is especially valuable if an experi-
ment desires to examine the effects of a gene expressed at
different levels. Using construct 11, for example, one may
separate cells with different levels of shRNA expression.
Alternatively, one may establish the stably transfected cell
lines that express different levels of shRNA using the sorted
cells from the FACS, as demonstrated in Figure 4D. A further
utility of this Pol II construct is that by replacing the ubiquitous
Pol II promoter with various cell type-specific Pol II pro-
moters, cell-specific gene silencing may be accomplished
in vivo. In addition, various temporally inducible Pol II pro-
moters, e.g. the tetracycline- or ecdysone-inducible promoters,
can be used to temporally control gene silencing.
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